Genetron Health Introduces Illumina HiSeq X Ten Sequencing Platform to Advance Global Precision Oncology
On April 25, 2016, Genetron Health announced the formal introduction of the Illumina HiSeq X Ten, the sequencing system with the highest throughput and efficiency globally, to meet the company’s needs in clinical diagnostics and scientific research.
It is reported that Genetron Health has established an internationally advanced, diversified molecular testing technology platform and a bioinformatics analysis platform. The company has set up dual R&D centers in North Carolina, USA, and Beijing, China; three clinical medical testing centers located in Beijing, Shanghai, and Hangzhou, with a total area exceeding 8,000 square meters; and sales centers covering multiple regions across North, South, East, and Southwest China. Leveraging its own foundations in genomics research and clinical translation capabilities, Genetron Health will build the “Cancer Genetic Testing System Engineering” project with the support of X Ten, continuing to serve a broad base of scientific research institutions and clinical customers in China and around the world.
Continue to Expand Whole-Genome Sequencing Capabilities
Genetron Health is one of the first gene technology companies in China to enter the field of cancer precision medicine. Since its inception, it has established a strategic framework that advances both medical scientific research and clinical operations in parallel. After years of dedicated development, Genetron Health has built robust scientific research capabilities and a comprehensive portfolio of clinical diagnostic and therapeutic products: asThe first in China to integrate all aspects of cancer genetic risk assessment, early screening, molecular pathology diagnosis, postoperative monitoring, and treatment, effectively combining gene sequencing with precision immunotherapy.As an innovative enterprise, Genetron Health is committed to assisting medical experts in providing reliable molecular diagnostic and therapeutic solutions, as well as professional cancer genetic risk assessments, for cancer patients and individuals at high risk of developing cancer.
Genetron Health has always regarded scientific research and product development as the soul and core competitiveness of the enterprise., making relentless investments in this field. Notably, Genetron Health’s research team boasts over two decades of experience in cancer genetics research and clinical translation, with dozens of top-tier research publications and multiple internationally leading patents. Over the past two years, it has collaborated extensively with China’s top cancer hospitals and research institutions, publishing in “Nature GeneticsPublished six research papers in top-tier academic journals worldwide. Meanwhile, Genetron Health has established long-term partnerships with the two most prestigious cancer research centers in the United States—Duke University and Johns Hopkins University—gaining access to the world’s most cutting-edge cancer research technologies. The company has forged deep collaborations with Duke University’s Laboratory for Cancer Genome Sciences and Brain Tumor Research Center, and has entered into an exclusive strategic partnership with PersonalGenomic Diagnostics, a genetic testing company co-founded by Professor Bert Vogelstein of Johns Hopkins University, thereby leading the development of molecular diagnosis and treatment of cancer both domestically and internationally.
Yan Hai, Chief Scientist of Genetron Health and Distinguished Professor at Duke University in the United States, stated: “Leveraging the powerful sequencing capabilities of the HiSeq X Ten platform, Genetron Health is able to further conduct high-quality, high-coverage whole-genome sequencing, bringing new breakthroughs and deeper insights to human genome research. In the future, Genetron Health will continue to promote in-depth collaboration with major hospitals and research institutions, committed to making genetic and clinical big data more practically benefit patients and the broader health-conscious population. While providing better services, we aim to support new explorations and breakthroughs in domestic research on cancer and complex diseases.”
Global Vision, Global Layout: Genetron Health Deepens Its Roots in the Chinese Market
Genetron Health CEO Wang Sizhen stated, “Following the official launch last year of Genetron Health’s Beijing R&D and Production Center and its R&D center in North Carolina’s Research Triangle Park—known as the ‘Eastern Silicon Valley’ of the United States—this significant investment in cutting-edge gene sequencing technology further strengthens Genetron Health’s corporate capabilities. Moving forward, we will continue to collaborate with leading international sequencing manufacturers, technology companies, and pharmaceutical firms, leveraging Genetron Health’s robust medical translation capabilities to jointly advance cancer scientific research and serve cancer patients in China.”
Genetron Health’s diverse, international team comprises experts from various fields, including cancer genetics, molecular biology, bioinformatics, pharmacology, clinical pathology, and clinical medicine, establishing an internationally standardized multidisciplinary collaboration system for precise cancer diagnosis and treatment. Meanwhile, Genetron Health’s collaborations with Duke University and Johns Hopkins University have facilitated the company’s efficient global expansion. Furthermore, Genetron Health has built internationally advanced, diversified molecular testing and bioinformatics analysis platforms, established dual R&D centers in the United States and China, and engaged in clinical, scientific research, and data analysis collaborations with top pharmaceutical companies in both countries. Additionally, Genetron Health’s product design consistently adheres to international frameworks and visions; its molecular diagnostic services and test kits are developed in alignment with a global development architecture, ensuring better suitability for both the Chinese and international markets.